Accent Therapeutics, a clinical-stage biopharmaceutical company, is at the forefront of developing small molecule precision cancer therapies targeting critical intracellular dependencies across various cancer types. Leveraging expertise in RNA-modifying proteins (RMPs) and strategic mapping of the RMP space, the company is focused on creating biomarker-driven cancer medicines that could revolutionize oncology treatments. Accent’s lead programs, including ATX-559 and ATX-295, are currently undergoing Phase 1/2 clinical evaluations, with a strong emphasis on addressing unmet needs in cancer care. For more information on Accent’s innovative approach to cancer therapy, visit their website or follow them on LinkedIn.
Read more from kxan.com
